Business Monitor International

Sudan & South Sudan Pharmaceuticals & Healthcare Report

Published 12 February 2014

  • 51 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
Sudan & South Sudan Pharmaceuticals & Healthcare Report

BMI View: Despite an improvement in Suda n's Pharmaceutical Risk/Reward R atings, we note that risks in the country far outweigh any possible rewards for pharmaceutical firms. This is due to a variety of reasons, some of which are industry-specific (eg, Sudan's failure to pay and lack of patent respect) and others country-specific (such as extensive bureaucracy, rampant corruption and unrests). Consequently, we do not expect the market to be of particular interest to foreign pharmaceutical players.

Headline Expenditure Projections

  • Pharmaceuticals: SDG2.60bn (US$560mn) in 2013 to SDG3.28bn (US$540mn) in 2014; +26.2% in local currency terms and -3.3% in US dollar terms.

  • Healthcare: SDG25.37bn (US$5.42bn) in 2013 to SDG34.51bn (US$5.65bn) in 2014; +36.0% in local currency terms and 4.2% in US dollar terms.

Risk/Reward Ratings

Sudan's Pharmaceutical Risk/Reward Rating (RRR) score for Q214 is 30.7. This is significantly lower than the MEA regional average score of 42.3, and places it 27th of 30 countries in the region. We note that the country scores below average for all indicators under industry and country risks and rewards. This is largely due to its small market size and poor economic and political environment.

Key Trends And Developments

  • In January 2014, Doctors Without Borders (MSF) stated that the South Sudan healthcare system was being severely strained by more than five weeks of fighting, with many hospitals located in conflict areas shut down. In the largest state of South Sudan, Jonglei, only the town of Lankien has a functioning secondary hospital.

  • In November 2013, Sudan's Drug Importers Chamber (DIC) revealed that 31 foreign pharmaceutical companies have 'refused to deal with the country' until outstanding credits amounting to US$90mn are paid. The companies have accused the Central Bank of Sudan (CBoS) of failing to provide the required foreign exchange.

BMI Economic View: We expect that Sudan's economy will grow at a quicker pace than in...

Table of Contents

BMI Industry View
Business Environment
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales Indicators, 2009-2017
Healthcare Market Forecast
Table: Healthcare Expenditure Indicators, 2009-2017
Table: Healthcare Governmental Indicators, 2009-2017
Table: Healthcare Private Indicators, 2009-2017
Macroeconomic Forecasts
Table: Sudan - Economic Activity
Industry Risk Reward Ratings
Middle East And Africa Risk/Reward Ratings
Sudan Risk/Reward Ratings
Market Overview
Industry Trends And Developments
Regulatory Development
Regulatory Regime
Demographic Forecast
Table: Sudan's Population By Age Group, 1990-2020 ('000)
Table: Sudan's Population By Age Group, 1990-2020 (% of total)
Table: Sudan's Key Population Ratios, 1990-2020
Table: Sudan's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Risk/Reward Ratings Indicators
Indicator Weightings

The Sudan & South Sudan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sudan & South Sudan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sudanese, Sudanese pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Sudan, South Sudan to test other views - a key input for successful budgeting and strategic business planning in the Sudanese, Sudanese pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Sudanese, Sudanese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sudan, South Sudan.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.


BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%


'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc